Fresolimumab

{
  "id": "MLC-T-ONC-003348",
  "term": "Fresolimumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of breast cancer that has spread to other parts of the body. It is also being studied in the treatment of other cancers and conditions. Fresolimumab binds to a protein called transforming growth factor-beta (TGF-beta), which is found on some cancer cells. Fresolimumab may help keep cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. It is a type of monoclonal antibody and a type of antiangiogenesis agent. Also called anti-TGF-beta monoclonal antibody GC1008 and GC1008.",
    "A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells."
  ],
  "synonyms": [
    "anti-TGF-beta monoclonal antibody GC1008",
    "GC1008",
    "human anti-TGF-beta monoclonal antibody GC1008"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/fresolimumab/"
}